Unknown

Dataset Information

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.


ABSTRACT:

Background

β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology.

Methods

Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging.

Results

Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher r

SUBMITTER: Doecke JD 

PROVIDER: S-EPMC7110644 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature